Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A single ultrasound exam may do double duty for liver disease. A multicenter study of 410 patients found that a novel LIID score accurately detected metabolic dysfunction-associated steatohepatitis (MASH), while liver stiffness measurement on the same device excelled at identifying advanced fibrosis — potentially sparing many patients an invasive biopsy.
One ultrasound, two answers: a smarter way to assess liver disease
Liver biopsy has long been the gold standard for diagnosing MASH and staging fibrosis — but it's invasive, costly, and not without risk. A new multicenter study out of China suggests a single ultrasound session could change that. Researchers validated a quantitative ultrasound-derived liver inflammation and injury detection (LIID) score alongside liver stiffness measurement (LSM) in 410 patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) across 10 hospitals.
The LIID score showed acceptable accuracy for detecting MASH, while LSM demonstrated high accuracy for identifying advanced fibrosis — and both were measured on the same device in one sitting.
By the Numbers
Why it matters: Combining LIID and LSM in one ultrasound platform offers a noninvasive, streamlined approach to diagnosing and staging liver disease — potentially reducing the need for biopsies and making liver assessment more accessible and cost-effective in clinical practice.
